Chong Kun Dang Pharmaceutical Corp.
🇰🇷South Korea
- Country
- 🇰🇷South Korea
- Ownership
- Public
- Established
- 1941-01-01
- Employees
- 2.3K
- Market Cap
- -
- Website
- http://www.ckdpharm.com
Study to Evaluate the Safety and Pharmacokinetics of CKD-379
Phase 1
Active, not recruiting
- Conditions
- Type II Diabetes Mellitus
- Interventions
- Drug: CKD-379Drug: D759+D745+D029+D150
- First Posted Date
- 2023-07-19
- Last Posted Date
- 2023-07-19
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 32
- Registration Number
- NCT05952219
- Locations
- 🇰🇷
Chonbuk National University Hospital, Jeonju, Korea, Republic of
Clinical Trial to Evaluate the Efficacy and Safety of D064 and D702 Combination Therapy
Phase 3
Completed
- Conditions
- Essential Hypertension
- Interventions
- Drug: D064, D702, placebo of D660Drug: D660, placebo of D064, placebo of D702
- First Posted Date
- 2023-07-05
- Last Posted Date
- 2024-06-04
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 346
- Registration Number
- NCT05931224
- Locations
- 🇰🇷
Seoul National University Bundang Hospital, Seongnam, Bundang-gu, Korea, Republic of
A Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetics of D745, D759, and D150
Phase 1
Completed
- Conditions
- Diabetes type2
- Interventions
- Drug: D745, D759, D150
- First Posted Date
- 2023-07-03
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 24
- Registration Number
- NCT05928637
- Locations
- 🇰🇷
Catholic Hospital, Seoul, Seoul, Korea, Republic of
Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetic After Oral Administration of CKD-341 and D958 in Healthy Adults
Phase 1
Completed
- Conditions
- Hypertension
- Interventions
- Drug: CKD-341, D958
- First Posted Date
- 2023-06-27
- Last Posted Date
- 2024-02-05
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 48
- Registration Number
- NCT05921435
- Locations
- 🇰🇷
Chungbuk National University Hospital, Cheongju-si, Korea, Republic of
Evaluate the Pharmacokinetics and Safety Between the Treatment of CKD-383 and Treatment of CKD-501, D745, D150, and D029
Phase 1
Completed
- Conditions
- Type 2 Diabetes
- Interventions
- Drug: CKD-383Drug: CKD-501, D745, D150, D029
- First Posted Date
- 2023-06-09
- Last Posted Date
- 2024-01-23
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 30
- Registration Number
- NCT05897216
- Locations
- 🇰🇷
CHA Bundang Medical Center, CHA University, Seongnam-si, Bundang, Korea, Republic of
A Clinical Trial to Compare the Pharmacokinetic and Safety of CKD-828 20/1.25mg
Phase 1
Completed
- Conditions
- Hypertension
- Interventions
- Drug: CKD-828, D064, D702
- First Posted Date
- 2023-05-31
- Last Posted Date
- 2023-10-31
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 44
- Registration Number
- NCT05881707
- Locations
- 🇰🇷
Jeonbuk National University Hospital, Seoul, Korea, Republic of
Clinical Trial to Investigate the Pharmacokinetics and Safety After Oral Administration of CKD-378 and Co-administration of D745, D150, D029 in Healthy Adults
Phase 1
Completed
- Conditions
- Type II Diabetes
- Interventions
- Drug: CKD-378 (low-dose)
- First Posted Date
- 2023-05-31
- Last Posted Date
- 2023-12-19
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 23
- Registration Number
- NCT05881213
- Locations
- 🇰🇷
Severance Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic of
A Clinical Trial to Evaluate the Blood Pressure Control of Telmisartan or Losartan in Essential Hypertensive Patients With Metabolic Syndrome
Phase 4
Not yet recruiting
- Conditions
- Essential HypertensionMetabolic Syndrome
- Interventions
- First Posted Date
- 2023-05-06
- Last Posted Date
- 2023-05-06
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 116
- Registration Number
- NCT05843162
A Clinical Trial to Compare the Pharmacokinetic and Safety of CKD-828
Phase 1
Completed
- Conditions
- Hypertension
- Interventions
- Drug: CKD-828, D064, D701
- First Posted Date
- 2023-04-28
- Last Posted Date
- 2023-08-25
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 43
- Registration Number
- NCT05834595
- Locations
- 🇰🇷
Central hospital, Gyeonggi-do, Korea, Republic of
Evaluate the Pharmacokinetics and Safety Between the Administration of CKD-383 and the Co-administration of CKD-501, D744, and D150
Phase 1
Completed
- Conditions
- Type 2 Diabetes
- Interventions
- Drug: CKD-383Drug: CKD-501, D744, D150
- First Posted Date
- 2023-04-18
- Last Posted Date
- 2024-01-23
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 32
- Registration Number
- NCT05816759
- Locations
- 🇰🇷
CHA Bundang Medical Center, CHA University, Seongnam-si, Bundang, Korea, Republic of
© Copyright 2025. All Rights Reserved by MedPath